It was developed in the early 1990s by the Danish pharmaceutical company Novo Nordisk, who were looking for a long-acting yet therapeutically effective treatment of type 2 diabetes [1]
Similarly, Figures 5G and H show that PNP-1-10-0.05 Sema-1.8 mg/mL hydrogel resulted in sustained glucose lowering compared to the bolus injection, maintaining efficacy across the cohort
However, regular antacid use can interfere with nutrient absorption over time
Our reduced L-glutathione, on the other hand, is 100% produced by non-GMO fermentation of glucose
Treatment duration and dose are based on clinical studies cited and discussed in this review, and are generally indicative of effective dose and time to see a significant clinical response
Every few decades medicine gets a class of drugs that changes the operating model, not just outcomes